GeneDx Holdings Corp
NASDAQ:WGS

Watchlist Manager
GeneDx Holdings Corp Logo
GeneDx Holdings Corp
NASDAQ:WGS
Watchlist
Price: 158.96 USD -1.85% Market Closed
Market Cap: 4.6B USD

GeneDx Holdings Corp
Cash & Cash Equivalents

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

GeneDx Holdings Corp
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
GeneDx Holdings Corp
NASDAQ:WGS
Cash & Cash Equivalents
$85.2m
CAGR 3-Years
-40%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
Quest Diagnostics Inc
NYSE:DGX
Cash & Cash Equivalents
$432m
CAGR 3-Years
-15%
CAGR 5-Years
-23%
CAGR 10-Years
13%
CVS Health Corp
NYSE:CVS
Cash & Cash Equivalents
$9.1B
CAGR 3-Years
-19%
CAGR 5-Years
0%
CAGR 10-Years
12%
Cigna Corp
NYSE:CI
Cash & Cash Equivalents
$6B
CAGR 3-Years
-5%
CAGR 5-Years
2%
CAGR 10-Years
10%
Laboratory Corporation of America Holdings
NYSE:LH
Cash & Cash Equivalents
$598.1m
CAGR 3-Years
13%
CAGR 5-Years
-2%
CAGR 10-Years
-2%
Guardant Health Inc
NASDAQ:GH
Cash & Cash Equivalents
$580m
CAGR 3-Years
54%
CAGR 5-Years
32%
CAGR 10-Years
N/A
No Stocks Found

GeneDx Holdings Corp
Glance View

GeneDx Holdings Corp. holds a prominent spot in the realm of genetic testing and diagnostics, intertwining advanced technology with healthcare to create a substantial impact in personalized medicine. Originally founded with the mission to provide accessible genetic testing services, the company has evolved into a pivotal player in identifying rare genetic disorders through its specialized sequencing techniques. By leveraging next-generation sequencing (NGS), GeneDx can efficiently decode vast arrays of genetic information, enabling healthcare providers to diagnose and manage hereditary conditions more accurately. Their comprehensive test offerings cover everything from whole exome sequencing to disease-specific panels, catering to the needs of patients and clinicians alike. This tailored approach not only drives innovation but also establishes a firm foundation in genetic diagnostics, addressing some of the most pressing needs in modern medicine. In terms of revenue generation, GeneDx’s business model thrives on its collaborations with healthcare institutions, insurers, and research organizations. The company's ability to reduce the time and cost involved in traditional diagnostics creates a clear value proposition, encouraging widespread adoption of its services. Insurance reimbursements play a crucial role, as more healthcare policies expand to include genetic testing due to its significant potential for early disease detection and management. Moreover, strategic partnerships and continuous investments in research and development allow GeneDx to stay at the forefront of genomic insights, further strengthening its market position. By staying ahead of industry trends and focusing on expanding access to genetic information, GeneDx establishes itself not only as a leader in diagnostics but also as an integral force in the broader healthcare ecosystem, ensuring sustained growth and relevance.

WGS Intrinsic Value
49.47 USD
Overvaluation 69%
Intrinsic Value
Price

See Also

What is GeneDx Holdings Corp's Cash & Cash Equivalents?
Cash & Cash Equivalents
85.2m USD

Based on the financial report for Dec 31, 2024, GeneDx Holdings Corp's Cash & Cash Equivalents amounts to 85.2m USD.

What is GeneDx Holdings Corp's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-6%

Over the last year, the Cash & Cash Equivalents growth was -15%. The average annual Cash & Cash Equivalents growth rates for GeneDx Holdings Corp have been -40% over the past three years , -6% over the past five years .

Back to Top